PCI Pharma Services To Acquire Fill-Finish CDMO Ajinomoto Althea
PCI Pharma Services, a Philadelphia, Pennsylvania-based CDMO, has agreed to acquire the entire equity stake in Ajinomoto Althea, a San Diego, California-based sterile fill–finish CDMO and 100% subsidiary of the Japanese multinational conglomerate, Ajinomoto Co.
Althea provides aseptic fill–finish services at clinical and commercial scales and is part of Ajinomoto Bio-Pharma Services, a CDMO of drug substances (small molecules and biologics, including antibody drug conjugates [ADCs], oligonucleotides and peptides, and gene therapies) and sterile drug-product manufacturing. Under the agreement, Althea will be separated from Ajinomoto Bio-Pharma Services, and all other Ajinomoto Bio-Pharma Services will continue to operate globally as part of Ajinomoto Group.
Scheduled for completion in May 2025, the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges, including isolator technology for these formats, as well as high-potent manufacturing suitable for antibody drug conjugates ADCs.
